Cited by 227Genetic Neurodegenerative DiseasesGenetic factors in colorectal cancerHereditary Neurological Disorders

DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases

Open access
Bettencourt, Conceição, Hensman‐Moss, Davina, Flower, Michael, Wiethoff, Sarah, Brice, Alexis, Goizet, Cyril, Stevanin, Giovanni, Koutsis, Georgios +17 more·2016·Annals of Neurology

Abstract

Objective: The polyglutamine diseases, including Huntington's disease (HD) and multiple spinocerebellar ataxias (SCAs), are among the commonest hereditary neurodegenerative diseases. They are caused by expanded CAG tracts, encoding glutamine, in different genes. Longer CAG repeat tracts are associated with earlier ages at onset, but this does not account for all of the difference, and the existence of additional genetic modifying factors has been suggested in these diseases. A recent genome‐wide association study (GWAS) in HD found association between age at onset and genetic variants in DNA repair pathways, and we therefore tested whether the modifying effects of variants in DNA repair genes have wider effects in the polyglutamine diseases. Methods: We assembled an independent cohort of 1,462 subjects with HD and polyglutamine SCAs, and genotyped single‐nucleotide polymorphisms (SNPs) selected from the most significant hits in the HD study. Results: In the analysis of DNA repair genes as a group, we found the most significant association with age at onset when grouping all polyglutamine diseases (HD+SCAs; p = 1.43 × 10 –5 ). In individual SNP analysis, we found significant associations for rs3512 in FAN1 with HD+SCAs ( p = 1.52 × 10 –5 ) and all SCAs ( p = 2.22 × 10 –4 ) and rs1805323 in PMS2 with HD+SCAs ( p = 3.14 × 10 –5 ), all in the same direction as in the HD GWAS. Interpretation: We show that DNA repair genes significantly modify age at onset in HD and SCAs, suggesting a common pathogenic mechanism, which could operate through the observed somatic expansion of repeats that can be modulated by genetic manipulation of DNA repair in disease models. This offers novel therapeutic opportunities in multiple diseases. Ann Neurol 2016;79:983–990

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.24656

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CAG expansion in HD is dependent upon DNA repair proteins such as OGG1, MLH1, and MSH2.

    “Notably, CAG expansion has been found to be dependent upon DNA repair proteins such as OGG1, MLH1, and MSH2, whose detection of oxidized or mismatched bases in these repetitive elements could potentially elicit erroneous repair, leading to CAG expansion (Kovtun et al, 2007; Bettencourt et al, 2016; Pinto et al, 2013; Manley et al, 1999; Lee et al, 2017, 1).”

    From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Bettencourt et al, 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bettencourt, C., Hensman‐Moss, D., Flower, M., Wiethoff, S., Brice, A., Goizet, C., Stevanin, G., Koutsis, G., Karadima, G., Panas, M., Yescas‐Gómez, P., García‐Velázquez, L. E., Alonso‐Vilatela, M. E., Lima, M., Raposo, M., Traynor, B., Sweeney, M., Wood, N., Giunti, P., The SPATAX Network, Durr, A., Holmans, P., Houlden, H., Tabrizi, S. J., & Jones, L.
Affiliations
  • National Hospital for Neurology and Neurosurgery (GB)
  • Department of Neurodegenerative Disease, Institute of Neurology University College London London WC1N 3BG United Kingdom
  • UCL Queen Square Institute of Neurology (GB)
  • Hertie Institute for Clinical Brain Research (DE)
  • Centre National de la Recherche Scientifique (FR)
  • Université de Bordeaux (FR)
  • Inserm U 1127, CNRS UMR 7225, Sorbonne Universités UPMC University Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière (ICM) Paris France
  • National and Kapodistrian University of Athens (GR)
  • Neurogenetics Unit, 1st Department of Neurology University of Athens Medical School, Eginition Hospital 115 28 Athens Greece
  • Neurogenetics Department, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez” Mexico City CP14269 Mexico
  • Instituto Nacional de Neurología y Neurocirugía (MX)
  • Universidade dos Açores (PT)
  • National Institutes of Health (US)
  • University College London Hospitals NHS Foundation Trust (GB)
  • Cardiff University (GB)
Corresponding author
Jones, Lesley
Venue
Annals of Neurology
Publisher
Wiley
Published
2016-05-06
Volume
79
Issue
6
Pages
983-990
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2342089554
Cited by
227
References
41
Citations by year
2026: 8 · 2025: 17 · 2024: 24 · 2023: 14 · 2022: 26 · 2021: 36 · 2020: 33 · 2019: 23 · 2018: 30 · 2017: 12 · 2016: 3
FWCI
12.65
Type
journal article
Language
en
Open access
Locations
  • Annals of Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • HAL (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Wellcome Trust (FP7/2007–2013, MR/L010305/1, WT093205 MA, 305121, WT104033/Z/14/Z)
  • Multiple System Atrophy Trust (WT093205MA)
  • National Institute for Health and Care Research (WT093205MA, ACF-2009-18-016, FP7/2007–2013, NF-SI-0515-10082)
  • Brain Research Trust
  • University College London (WT093205MA)
  • European Commission (2007–2013, FP7 2007-2013, FP7/2007, 305121)
  • University College London Hospitals NHS Foundation Trust
  • Medical Research Council (MR/L02053X/1, FP7/20072013, MR/P007015/1, MR/L012936/1, MR/J003832/1, MR/L010305/1, MC_PC_14108, MR/J004758/1, WT093205 MA)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
polyglutamine diseases, Huntington's disease, spinocerebellar ataxia, DNA repair genes, age of onset, genetic modifiers, CAG repeat expansion, somatic repeat expansion, FAN1, PMS2, single nucleotide polymorphisms, neurodegenerative diseases
MeSH terms
Mismatch Repair Endonuclease PMS2, DNA Repair, Endodeoxyribonucleases, Exodeoxyribonucleases, Humans, Huntington Disease, Mutation, Age of Onset, Trinucleotide Repeat Expansion, Polymorphism, Single Nucleotide, Spinocerebellar Ataxias, Genome-Wide Association Study, Multifunctional Enzymes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review